Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
Follow MESO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
102.91 | 161.55 | 62.96 | 71.32 | 60.45 | 136.88 | 129.33 | 50.43 | 37.76 | 45.76 |
Receivables |
57.66 | 14.87 | 20.95 | 7.00 | 4.40 | 4.84 | 1.57 | 4.06 | 50.37 | 3.74 |
Inventory |
28.11 | 22.25 | — | — | — | — | — | — | — | — |
Total current assets |
197.49 | 204.35 | 86.46 | 81.66 | 69.84 | 148.23 | 136.55 | 62.52 | 101.07 | 63.61 |
Property, Plant, Equpment (Net) |
1.82 | 1.70 | 1.11 | 1.36 | 2.05 | 3.02 | 2.29 | 0.83 | 1.08 | 1.81 |
Long-Term Investments |
— | 1.39 | 1.01 | 1.76 | 1.76 | 2.08 | 1.87 | 2.32 | 2.32 | 2.00 |
Goodwill and Intangible Assets (Total) |
566.37 | 571.83 | 575.74 | 577.18 | 578.65 | 580.55 | 581.60 | 583.13 | 584.61 | 586.35 |
Long-term assets (Other) |
1.20 | 1.30 | 2.10 | 2.33 | 1.93 | 1.72 | 3.31 | 3.32 | 3.36 | 1.92 |
Total non-current assets |
575.59 | 580.33 | 582.69 | 587.76 | 592.30 | 596.49 | 597.05 | 589.59 | 591.37 | 592.08 |
Total Assets |
773.08 | 784.68 | 669.15 | 669.42 | 662.14 | 744.72 | 733.60 | 652.12 | 692.44 | 655.69 |
Accounts Payable |
46.81 | 19.08 | 7.07 | 20.15 | 23.08 | 19.60 | 24.97 | 13.06 | 18.92 | 21.81 |
Current Part of Debt |
10.60 | 54.16 | 13.86 | 5.95 | 5.02 | 53.20 | 32.46 | 14.01 | — | — |
Other current liabilities |
20.68 | 26.71 | 49.69 | 11.83 | 20.09 | 18.71 | 29.20 | 17.26 | 5.08 | 14.87 |
Total current liabilities |
81.11 | 102.63 | 73.24 | 41.98 | 51.37 | 94.27 | 90.14 | 44.33 | 24.00 | 36.67 |
Long Term Debt (Total) |
108.64 | 67.74 | 100.48 | 102.81 | 91.62 | 41.05 | 57.02 | 67.28 | 59.40 | — |
Long Term Tax Liability (Deferred) |
— | — | — | — | — | — | 0.73 | 11.12 | 20.08 | 49.29 |
Non-current Liabilities (Other) |
9.86 | 13.29 | 13.12 | 19.11 | 15.02 | 19.52 | 30.06 | 48.33 | 42.96 | 52.96 |
Total non-current liabilities |
123.56 | 84.62 | 115.56 | 125.60 | 113.73 | 69.05 | 94.13 | 126.73 | 122.43 | 102.25 |
Total liabilities |
204.67 | 187.24 | 188.80 | 167.58 | 165.10 | 163.32 | 184.28 | 171.06 | 146.44 | 138.92 |
Common Stock (Net) |
1,530.77 | 1,508.85 | 1,310.81 | 1,249.12 | 1,165.31 | 1,163.15 | 1,051.45 | 910.41 | 889.48 | 830.43 |
Retained Earnings |
(1,068.40) | (1,010.90) | (908.76) | (820.80) | (738.92) | (647.57) | (548.76) | (469.99) | (380.19) | (344.90) |
Shareholders Equity (Other) |
106.03 | 99.50 | 78.30 | 73.52 | 70.65 | 65.81 | 46.63 | 40.64 | 36.72 | 31.24 |
Common Equity (Total) |
568.41 | 597.44 | 480.36 | 501.84 | 497.04 | 581.40 | 549.33 | 481.05 | 546.01 | 516.77 |
Shareholders Equity (Total) |
568.41 | 597.44 | 480.36 | 501.84 | 497.04 | 581.40 | 549.33 | 481.05 | 546.01 | 516.77 |
Shareholders Equity and Liabilities (Total) |
773.08 | 784.68 | 669.15 | 669.42 | 662.14 | 744.72 | 733.60 | 652.12 | 692.44 | 655.69 |
Shares (Common) |
129.67 | 127.99 | 114.12 | 81.37 | 65.05 | 64.87 | 58.05 | 49.51 | 47.91 | 42.82 |
Shareholders Equity (Tangible) |
2.04 | 25.62 | (95.38) | (75.34) | (81.61) | 0.85 | (32.27) | (102.07) | (38.60) | (69.58) |
Net Debt |
16.32 | (39.66) | 51.39 | 37.45 | 36.19 | (42.64) | (39.85) | 30.86 | 21.63 | (45.76) |
Total Debt |
119.24 | 121.89 | 114.35 | 108.76 | 96.63 | 94.25 | 89.48 | 81.29 | 59.40 | — |